* Celgene Corp., of Warren, N.J., supplied thalidomide for use in a study testing it against multiple myeloma, the most common blood cancer. In a study of 26 patients, the disease ceased to progress in almost 60 percent of patients given thalidomide. Some patients experienced a reduction in tumor growth and three patients approached a complete response.
* Delsys Pharmaceutical Corp., of Princeton, N.J., received a $3 million equity investment from an affiliate of Elan Corp. plc, of Dublin, Ireland. The investment follows the July announcement of the companies' collaboration. They have established a joint venture to develop and commercialize controlled-release products.
* Incyte Pharmaceuticals Inc., of Palo Alto, Calif., expanded its relationship with Pfizer Inc., of New York, to include a license to Incyte's LifeTools bioinformatics software and LifeArray microarray data analysis and management software. The companies' collaboration was begun in June 1994 with the signing of a $25 million deal. (See BioWorld Today, June 24, 1994, p. 1.)
* Sequenom Inc., of San Diego, said its DNA MassArray Automated Process Line is operational in its Hamburg, Germany, facility. The line is the first DNA analytical system that can be operated under conditions characteristic of large-scale industrial processes. A second system will be operational at the San Diego headquarters in the first quarter of next year.